Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Supernus Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $20.9M

Supernus Pharmaceuticals reported total revenues of $226.8 million for the third quarter of 2026, driven by net product sales and collaboration revenue from ZURZUVAE. While the company achieved net earnings of $20.9 million for the quarter, it recorded a net loss of $39.8 million for the first nine months of 2026, primarily due to $56.5 million in impairment charges.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue226.8192.1
Profit before tax22.7-58.0
Net income20.9-45.1
EPS (diluted, $ a share)$0.35$-0.80

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+18.0%
Operating margin9.3%
Source

10-Q filed with the SEC, NASDAQ: SUPN. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Supernus Pharmaceuticals, Inc.: key numbers

Share price
$28.83Close, Nov 16
Market cap
$1.68B
Shares outstanding
58.24MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Supernus Pharmaceuticals, Inc.

All →
10:51 AM ET 8-K
M&A Deal

Supernus Pharmaceuticals M&A Deal Update

Supernus Pharmaceuticals, Inc. notified Nasdaq of the completion of its merger on November 2, 2026, and requested the suspension and delisting of its common stock. The company intends to deregister its shares and suspend its reporting obligations under the Exchange Act as it will no longer be listed on any national securities exchange.

9:28 AM ET 8-K
M&A Deal

Supernus Pharmaceuticals M&A Deal with Indivior Pharmaceuticals, Inc.

Supernus Pharmaceuticals completed its previously announced merger with Indivior Pharmaceuticals, with Supernus becoming a wholly owned subsidiary of the combined entity, which has been renamed Supernus, Inc. Supernus stockholders received 1.5401 shares of the combined company for each share held, and the transaction was supported by a new $650 million senior secured term loan facility.

Counterparty
Indivior Pharmaceuticals, Inc.
4:09 PM ET 8-K
Financial Results

Supernus Pharmaceuticals Financial Results

Supernus Pharmaceuticals reported record Q3 2026 total revenues of $226.8 million, an 18% increase year-over-year, driven by strong performance from growth products like Qelbree and ZURZUVAE. The company also announced that its pending merger with Indivior Pharmaceuticals is expected to close on November 2, 2026. Additionally, the FDA recognized seven years of orphan-drug exclusivity for its Parkinson’s disease treatment, ONAPGO.

Counterparty
Indivior Pharmaceuticals, Inc.
Term
Q3 2026

“Our strong operating execution year-to-date delivered total revenue growth of 29%, which shows the continued momentum across our commercial portfolio, specifically our growth products. We look forward to closing the merger with Indivior next week, which will create a diverse CNS biopharmaceutical leader positioned to serve more patients and deliver long-term value for shareholders.”

Jack Khattar, President and Chief Executive Officer
4:42 PM ET 8-K
Deal Termination

Supernus Pharmaceuticals Deal Termination with UBS Bank USA

Supernus Pharmaceuticals terminated its uncommitted demand revolving credit line with UBS Bank USA on October 20, 2026. The termination was made in anticipation of the company's pending merger with Indivior Pharmaceuticals and the establishment of a new senior secured credit facility for the combined entity. There were no outstanding borrowings or early termination penalties associated with the cancellation.

Counterparty
UBS Bank USA
6:03 AM ET 8-K
Regulatory Approval

Supernus Pharmaceuticals Regulatory Approval

The FDA has recognized seven years of orphan-drug exclusivity for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in advanced Parkinson’s disease. The exclusivity period is retroactive to the drug's approval date of February 3, 2025, and the company has also submitted an sNDA for a second supplier to ensure long-term supply stability.

Term
7 years

“Securing orphan-drug exclusivity marks an important milestone for individuals and families navigating Parkinson's disease. This designation validates the urgent need for targeted therapies and helps safeguard continued innovation in a long-underserved community.”

Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals
4:11 PM ET 8-K
M&A Deal

Supernus Pharmaceuticals M&A Deal with Indivior Pharmaceuticals Inc.

Supernus Pharmaceuticals stockholders approved the company's acquisition by Indivior Pharmaceuticals at a special meeting held on October 15, 2026. Under the terms of the merger agreement, Supernus will become a wholly-owned subsidiary of Indivior. Stockholders also approved, on a non-binding basis, the merger-related compensation for the company's named executive officers.

Counterparty
Indivior Pharmaceuticals Inc.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.